This eBook analyses the routes biotech companies are taking to gain access to public markets. While Spacs had their moment in the sun, they are now widely perceived as a means for subpar companies to force their way into the market. We crunch the numbers to see if pharma and medtech companies had any serious success with Spacs – and whether the relatively few recent flotations have fared any better.
We also examine how the previous bull market has made conditions favourable for reverse mergers. This approach isn’t generally highly regarded, but there are plenty of zombie biopharma companies lurching around Nasdaq. With few other options available, we ask whether this poor reputation is justified.
Download the eBook now for data-driven insights on the tough realities facing pharma and biotech. A huge amount of cash has been splashed in the past few years, but was it money for nothing?